AOL News is joining forces with The Huffington Post to bring you the best original reporting, insight and opinion on the web. Join HuffPost Social News using your AOL account!

Orexigen Therapeutics News

Orexigen Therapeutics News From AOL News

FDA Panel Rejects Experimental Weight Loss Pill

Jul 15th 2010 – 6:56PM

GAITHERSBURG, MD. (July 15) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight. The Food and Drug Administration panel voted 10-6 against Vivus's Qnexa, citing...

Orexigen Therapeutics News From the Web

  • 02/14/11 Orexigen Therapeutics, Inc. under investor... Source: PR-inside.com - Austria After Orexigen Therapeutics announced on February 1 that the FDA rejected the weight loss drug Contrave an investigation for investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares over possible breaches of fiduciary duties was announced. you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
  • 08/12/10 SADIF Analytics rates Orexigen Therapeutics, Inc. as a... Source: PR-inside.com - Austria 2010-08-12 10:49:27 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Orexigen Therapeutics, Inc. and produced a report, rating the company's attractiveness to long-term investors.

Background on Orexigen Therapeutics

more at wikipedia »